![](https://investorshub.advfn.com/uicon/822788.png?cb=1664635735)
Friday, December 15, 2023 7:57:52 PM
Thanks for reposting your baseless opinions again, but your comments reflect disregard for the clinical data overall which include multiple clinical studies. Your comments also show disregard for the expertise and integrity of the physicians who led the trial.
Your disinformation about the design of the exemplary P3 is a distraction from the technology as a platform with potential combo indications beyond nGBM and rGBM.
Combo is King!
Research the interim survival data of the small but mighty PD1 combo study that is ongoing at UCLA today!
https://clinicaltrials.gov/study/NCT04201873
![](http://investorshub.advfn.com/uimage/uploads/2023/12/15/sxgipIMG_6924.jpeg)
UCLA, King’s College, JAMA Oncology, and Brown University are some excellent sources that you might want to consider in reference to the reputation of Northwest Biotherapeutics and those who choose to associate with the company, its SAB, and with the novel DCVax® technology.
The world-renowned doctors cited below worked on the P3 and were coauthors of a DCVax-L publication along with Dr. Bosch of Northwest Biotherapeutics.
Furthermore, both Liau and Ashkan have had the support their respective nations’ governments over many years. Ashkan is an adviser to the UK government, and Liau’s work has been supported by NIH peer-reviewed grants for 20 consecutive years.
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
![](http://investorshub.advfn.com/uimage/uploads/2023/12/10/qldhwIMG_6892.jpeg)
https://labusinessjournal.com/healthcare/national-academy-medicine-taps-ucla-neurosurgeon/
![](http://investorshub.advfn.com/uimage/uploads/2023/12/10/vvdqiIMG_6896.jpeg)
https://pubmed.ncbi.nlm.nih.gov/33789235/
https://www.societyns.org/about/officers-detail/linda-m-liau-md-phd-mba-4
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
— JAMA Oncology (@JAMAOnc) February 15, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) October 3, 2023
Great to see, congratulations Linda Liau winning the Charles B. Wilson Excellence Award 2023:
Established by the Brain Tumor Society in 2004, this award recognizes outstanding contributions of a clinician to the field of neuro-oncology.… pic.twitter.com/6L7rhyoNU4
https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/
![](http://investorshub.advfn.com/uimage/uploads/2023/12/10/xmhkhIMG_6893.jpeg)
https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020
![Bullish](/static/images/ih2-bull.png)
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM